• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate.神经内分泌肿瘤治疗的新进展——RADIANT-4、NETTER-1和替洛曲塞依替膦酸盐
Eur Endocrinol. 2016 Mar;12(1):44-46. doi: 10.17925/EE.2016.12.01.44. Epub 2016 Mar 15.
2
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.依维莫司、镥[177Lu]DOTATATE 和舒尼替尼治疗晚期、不可切除或转移性神经内分泌肿瘤且疾病进展：系统评价和成本效果分析。
Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.
3
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.替洛曲普明，一种新型血清素合成抑制剂，用于治疗类癌综合征和腹泻且奥曲肽控制效果不佳的患者。
Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10.
4
Management of Small Bowel Neuroendocrine Tumors.小肠神经内分泌肿瘤的管理
Cancers (Basel). 2019 Sep 18;11(9):1395. doi: 10.3390/cancers11091395.
5
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.胃肠道神经内分泌肿瘤的诊断和治疗：基于证据的加拿大共识。
Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. Epub 2016 May 17.
6
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.抑制血清素外周合成作为神经内分泌肿瘤的新靶点
Oncologist. 2016 Jun;21(6):701-7. doi: 10.1634/theoncologist.2015-0455. Epub 2016 Apr 22.
7
Lutetium oxodotreotide (Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.镥氧奥曲肽（Lu-Dotatate）治疗不可切除或转移性进展性胃肠胰神经内分泌肿瘤：苏格兰的成本效益分析。
BMC Cancer. 2021 Jan 5;21(1):10. doi: 10.1186/s12885-020-07710-7.
8
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.神经内分泌肿瘤的临床异质性会对其未来的治疗产生影响吗？近期试验的经验教训。
Curr Opin Oncol. 2016 Jul;28(4):359-66. doi: 10.1097/CCO.0000000000000299.
9
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.北美神经内分泌肿瘤学会关于中肠神经内分泌肿瘤监测与医学管理的共识指南
Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850.
10
Telotristat Etiprate alleviates rheumatoid arthritis by targeting LGALS3 and affecting MAPK signaling.替洛曲酯通过靶向半乳糖凝集素-3（LGALS3）并影响丝裂原活化蛋白激酶（MAPK）信号通路来缓解类风湿性关节炎。
Intractable Rare Dis Res. 2023 Feb;12(1):45-57. doi: 10.5582/irdr.2022.01121.

本文引用的文献

1
Changes in the Epidemiology of Neuroendocrine Tumours.神经内分泌肿瘤流行病学的变化
Neuroendocrinology. 2017;104(2):105-111. doi: 10.1159/000441897. Epub 2015 Oct 28.
2
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.长效可重复注射奥曲肽在神经内分泌肿瘤中的疗效：RADIANT-2安慰剂组事后分析
Endocr Relat Cancer. 2015 Dec;22(6):933-40. doi: 10.1530/ERC-15-0314. Epub 2015 Sep 15.
3
Carcinoid Heart Disease: From Pathophysiology to Treatment--'Something in the Way It Moves'.类癌性心脏病：从病理生理学到治疗——“其运动方式中的某些因素”
Neuroendocrinology. 2015;101(4):263-73. doi: 10.1159/000381930. Epub 2015 Apr 9.
4
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.替洛曲普明治疗类癌综合征：一项单臂、多中心试验。
J Clin Endocrinol Metab. 2015 Apr;100(4):1511-9. doi: 10.1210/jc.2014-2247. Epub 2015 Jan 30.
5
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.兰瑞肽治疗转移性胃肠胰神经内分泌肿瘤。
N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.
6
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.替洛曲普明，一种新型血清素合成抑制剂，用于治疗类癌综合征和腹泻且奥曲肽控制效果不佳的患者。
Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10.
7
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.国际原子能机构、欧洲核医学协会和核医学分子影像学会联合发布的神经内分泌肿瘤肽受体放射性核素治疗实践指南。
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
8
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.帕瑞肽（SOM230）治疗奥曲肽长效释放剂治疗抵抗或耐药的晚期神经内分泌肿瘤患者的疗效和耐受性：一项 II 期研究结果。
Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct.
9
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.依维莫司联合奥曲肽长效缓释剂治疗与类癌综合征相关的晚期神经内分泌肿瘤（RADIANT-2）：一项随机、安慰剂对照、3 期研究。
Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.
10
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).胃肠胰神经内分泌（包括类癌）肿瘤（NETs）管理指南。
Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.

神经内分泌肿瘤治疗的新进展——RADIANT-4、NETTER-1和替洛曲塞依替膦酸盐

New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate.

作者信息

Sbardella Emilia, Grossman Ashley

机构信息

Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK.

出版信息

Eur Endocrinol. 2016 Mar;12(1):44-46. doi: 10.17925/EE.2016.12.01.44. Epub 2016 Mar 15.

DOI:10.17925/EE.2016.12.01.44
PMID:29632589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5813460/
Abstract

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of radiolabelled Lu-DOTATATE in patients with mid-gut NETs, and the use of the 5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid syndrome.

摘要

神经内分泌肿瘤（NETs）是一组异质性肿瘤，近年来其发病率显著上升，而其最佳治疗方案仍存在争议。我们报告了其治疗方面的最新创新成果，特别是三项试验的结果，这些试验涉及雷帕霉素靶蛋白（mTOR）抑制剂依维莫司在肺/胃肠道（GI）起源的无功能NETs中的应用、首例针对中肠NETs患者的放射性标记镥- DOTATATE随机试验，以及5-羟色胺合成抑制剂替曲司特在类癌综合征患者中的应用。